New hope for Hard-to-Treat stomach and esophageal cancers: enhertu trial opens
NCT ID NCT07126561
First seen Jan 11, 2026 · Last updated May 02, 2026 · Updated 16 times
Summary
This study tests the drug Enhertu in people with advanced HER2-positive esophageal, stomach, or gastroesophageal junction cancer who have not had prior treatment for metastatic disease. About 43 participants with a lower performance status (ECOG 2) will receive Enhertu by IV every 3 weeks. The main goal is to see how many patients' tumors shrink, while also monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 POSITIVE NEWLY DIAGNOSED METASTATIC ESOPHAGEAL, GASTRIC, GEJ CANCER PATIENTS WITH AN ECOG PERFORMANCE STATUS OF 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.